title: Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization.
abstract: Basic fibroblast growth factor (FGF2) is constitutively expressed in the retina and its expression is increased by a number of insults, but its role in the retina is still uncertain. This study was designed to test the hypothesis that altered expression of FGF2 in the retina affects the development of retinal neovascularization. Mice with targeted disruption of the Fgf2 gene had no detectable expression of FGF2 in the retina by Western blot, but retinal vessels were not different in appearance or total area from wild-type mice. When FGF2-deficient mice were compared with wild-type mice in a murine model of oxygen-induced ischemic retinopathy, they developed the same amount of retinal neovascularization. Transgenic mice with a rhodopsin promoter/Fgf2 gene fusion expressed high levels of FGF2 in retinal photoreceptors but developed no retinal neovascularization or other abnormalities of retinal vessels; in the ischemic retinopathy model, they showed no significant difference in the amount of retinal neovascularization compared with wild-type mice. These data indicate that FGF2 expression is not necessary nor sufficient for the development of retinal neovascularization. This suggests that agents that specifically antagonize FGF2 are not likely to be useful adjuncts in the treatment of retinal neovascularization and therapies designed to increase FGF2 expression are not likely to be complicated by retinal neovascularization.
authors.affiliation: Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA.
authors.forename: H
authors.initials: H
authors.lastname: Ozaki
authors.forename: N
authors.initials: N
authors.lastname: Okamoto
authors.forename: S
authors.initials: S
authors.lastname: Ortega
authors.forename: M
authors.initials: M
authors.lastname: Chang
authors.forename: K
authors.initials: K
authors.lastname: Ozaki
authors.forename: S
authors.initials: S
authors.lastname: Sadda
authors.forename: M A
authors.initials: MA
authors.lastname: Vinores
authors.forename: N
authors.initials: N
authors.lastname: Derevjanik
authors.forename: D J
authors.initials: DJ
authors.lastname: Zack
authors.forename: C
authors.initials: C
authors.lastname: Basilico
authors.forename: P A
authors.initials: PA
authors.lastname: Campochiaro
mesh_terms: D000818:Animals; D017931:DNA Primers / Q000737:chemistry; D004195:Disease Models, Animal; D016222:Fibroblast Growth Factor 2 / Q000172:deficiency / Q000502:physiology*; D006801:Humans; D007124:Immunoenzyme Techniques; D007231:Infant, Newborn; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D016133:Polymerase Chain Reaction; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D012160:Retina / Q000378:metabolism / Q000473:pathology; D015861:Retinal Neovascularization / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology; D012171:Retinal Vessels / Q000378:metabolism / Q000473:pathology; D012178:Retinopathy of Prematurity / Q000150:complications / Q000378:metabolism / Q000473:pathology; D012243:Rhodopsin / Q000378:metabolism
chemical_list: D017931:DNA Primers; D011993:Recombinant Fusion Proteins; D016222:Fibroblast Growth Factor 2; D012243:Rhodopsin